Bottom line compliance for biotechnology: Six secrets

Authors

  • John Avellanet

DOI:

https://doi.org/10.5912/jcb288

Keywords:

compliance, regulation, quality systems, FDA

Abstract

Biotechnology executives frequently short-shrift one of the key indicators of return on investment when negotiating pharmaceutical partnerships, support or licensing: a compliance and quality system. Given the increasingly tight financial markets biotechnology executives must operate within, can a good quality system be established for less than the cost of an average car?

Downloads

Issue

Vol. 15 No. 3 (2009)

Section

Article